LOVENOX (PRESERVATIVE FREE) Drug Patent Profile

Which patents cover Lovenox (preservative Free), and when can generic versions of Lovenox (preservative Free) launch?

Lovenox (preservative Free) is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in LOVENOX (PRESERVATIVE FREE) is enoxaparin sodium. There are thirteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the enoxaparin sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lovenox (preservative Free)

A generic version of LOVENOX (PRESERVATIVE FREE) was approved as enoxaparin sodium by SANDOZ INC on November 28^th, 2011.

Summary for LOVENOX (PRESERVATIVE FREE)

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	25
DailyMed Link:	LOVENOX (PRESERVATIVE FREE) at DailyMed

Pharmacology for LOVENOX (PRESERVATIVE FREE)

Drug Class

Low Molecular Weight Heparin

Paragraph IV (Patent) Challenges for LOVENOX (PRESERVATIVE FREE)

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LOVENOX (PRESERVATIVE FREE)	Injection	enoxaparin sodium	100 mg/mL, 3 mL vials	020164	1	2006-12-07

US Patents and Regulatory Information for LOVENOX (PRESERVATIVE FREE)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-001	Mar 29, 1993	AP	RX	Yes	No
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-007	Jun 2, 2000	AP	RX	Yes	No
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-004	Mar 27, 1998	AP	RX	Yes	No
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-008	Jun 2, 2000	AP	RX	Yes	No

Expired US Patents for LOVENOX (PRESERVATIVE FREE)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-004	Mar 27, 1998
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-005	Mar 27, 1998
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-003	Mar 27, 1998
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-001	Mar 29, 1993

EU/EMA Drug Approvals for LOVENOX (PRESERVATIVE FREE)

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Techdow Pharma Netherlands B.V.	Inhixa	enoxaparin sodium	EMEA/H/C/004264Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis.	Authorised	no	yes	no	2016-09-15
Pharmathen S.A.	Thorinane	enoxaparin sodium	EMEA/H/C/003795Thorinane is indicated for adults for:, , - Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery., , - Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL)., , - Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism., , - Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA)., , - Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL)., , - Blood clot prevention in the extracorporeal circulation during haemodialysis., , Prevention and treatment of various disorders related to blood clots in adults.,	Withdrawn	no	yes	no	2016-09-14

International Patents for LOVENOX (PRESERVATIVE FREE)

See the table below for patents covering LOVENOX (PRESERVATIVE FREE) around the world.

Country	Patent Number	Title	Estimated Expiration
France	2663639	MELANGES DE POLYSACCHARIDES DE BAS POIDS MOLECULAIRES PROCEDE DE PREPARATION ET UTILISATION.
Spain	2036922	PROCEDIMIENTO DE OBTENCION DE MEZCLAS DE POLISACARIDOS DE BAJOS PESOS MOLECULARES.
World Intellectual Property Organization (WIPO)	8101004
Australia	6787081

LOVENOX (Preservative-Free): Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

LOVENOX (enoxaparin sodium) is a low molecular weight heparin (LMWH) anticoagulant used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent cardiac complications in patients with unstable angina or myocardial infarction. The preservative-free formulation is critical for specific patient populations, particularly those undergoing procedures where preservatives may cause adverse effects. This analysis examines the market dynamics and financial trajectory of LOVENOX (preservative-free), focusing on patent landscape, market share, competitive environment, and revenue generation.

What is the Patent Landscape for LOVENOX (Preservative-Free)?

The originator patent for enoxaparin sodium has expired. However, the complexity of LMWHs, particularly their manufacturing processes and specific formulations, has led to ongoing patent litigation and has supported market exclusivity for the branded product for an extended period.

• Original Patent Expiration: The primary patents covering the enoxaparin sodium molecule and its use have expired globally. For example, key U.S. patents related to enoxaparin expired in the early to mid-2010s.
• Formulation Patents: Sanofi, the originator, has historically maintained patents covering specific formulations, including preservative-free versions, and manufacturing processes. These patents have been a key defense against generic competition.
• Patent Litigation: The expiration of core patents has triggered numerous patent challenges and litigation. Generic manufacturers have sought to introduce their versions of enoxaparin, leading to legal battles over process patents, polymorphs, and bioequivalence.
• Regulatory Exclusivity: In some jurisdictions, regulatory exclusivities (e.g., New Chemical Entity exclusivity or orphan drug exclusivity) may have provided additional periods of protection, though these are distinct from patent protection.
• Current Patent Status: While the fundamental patents are expired, secondary patents and ongoing litigation continue to shape the market entry of generics. Decisions in patent courts regarding specific manufacturing processes or formulation patents can significantly impact the timeline for generic LOVENOX (preservative-free) availability. For instance, in the U.S., patent disputes have revolved around the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act), influencing generic approval timelines.

What is the Market Share and Competitive Landscape for LOVENOX (Preservative-Free)?

LOVENOX has held a dominant position in the LMWH market for many years. The preservative-free formulation specifically addresses a niche but critical need within the broader anticoagulant market.

• Market Dominance: Historically, LOVENOX has been the market leader in the LMWH segment, with significant market share in both hospital and outpatient settings.
• Generic Entry: The entry of generic enoxaparin sodium has been gradual and complex due to the patent challenges and the intricate nature of LMWH manufacturing. Generic versions are now available in many markets, directly competing with LOVENOX.
• Key Competitors:
  • LOVENOX (Sanofi): Remains a significant player, particularly in markets where patent protections or market inertia create barriers for generics.
  • Generic Enoxaparin Sodium: Multiple manufacturers now produce generic enoxaparin sodium. These include companies such as Teva Pharmaceuticals, Momenta Pharmaceuticals (now part of Sandoz), and others. The preservative-free versions of these generics are increasingly available.
  • Other LMWHs: While enoxaparin is the most widely used LMWH, other LMWHs like dalteparin (FRAGMIN) and tinzaparin (INNOHEP) compete in the broader anticoagulant space, though they may not offer direct preservative-free alternatives.
  • Direct Oral Anticoagulants (DOACs): DOACs such as rivaroxaban (XARELTO), apixaban (ELIQUS), and edoxaban (SAVAYSA) represent a significant competitive threat to LMWHs for certain indications, particularly in the long-term treatment and prevention of venous thromboembolism. They offer oral administration and often a simpler dosing regimen, but LMWHs like LOVENOX remain preferred in specific clinical scenarios, including acute coronary syndromes, renal impairment, and during certain surgical procedures, where the preservative-free formulation is crucial.
• Market Share Erosion: With the increasing availability and acceptance of generic enoxaparin sodium, particularly the preservative-free versions, LOVENOX has experienced and will continue to experience market share erosion. The price differential between the branded product and generics is a primary driver of this shift.
• Preservative-Free Specificity: The market for preservative-free enoxaparin is more specialized. While LOVENOX was a first-mover, generic manufacturers have also developed and obtained approval for preservative-free formulations, intensifying competition within this specific segment.

What is the Financial Trajectory of LOVENOX (Preservative-Free)?

The financial trajectory of LOVENOX (preservative-free) is characterized by its mature market status, the impact of generic competition, and ongoing revenue generation driven by its established clinical utility and demand in specific patient populations.

• Historical Revenue: LOVENOX has been a blockbuster drug for Sanofi, generating billions of dollars in annual revenue at its peak. For example, in 2011, Sanofi reported global sales of approximately €3.9 billion (around $5.5 billion at the time) for LOVENOX.
• Impact of Generic Entry: The introduction of generic enoxaparin sodium has significantly impacted LOVENOX’s revenue. Sanofi's reported sales for LOVENOX have declined considerably from their peak. For instance, in 2023, global sales for LOVENOX were reported at €807 million (approximately $875 million). This represents a substantial decrease from its peak sales years, directly attributable to generic competition.
• Preservative-Free Segment Contribution: While precise figures for the preservative-free formulation alone are not typically broken out by manufacturers in public financial reports, it represents a critical component of the overall LOVENOX sales. Its use in hospital settings and for specific procedures ensures continued demand, even as overall LOVENOX revenue declines.
• Generic Revenue Growth: Conversely, the market for generic enoxaparin sodium has seen substantial growth. The aggregated sales of all generic enoxaparin sodium products now exceed the sales of branded LOVENOX.
• Pricing Dynamics: Branded LOVENOX is priced at a premium compared to generic enoxaparin sodium. As generics gain market share, the overall revenue generated from enoxaparin sodium in the U.S. market, for example, has decreased due to lower average selling prices, despite increased volume.
• Future Outlook: The financial trajectory for branded LOVENOX (preservative-free) will likely continue to be one of declining sales due to ongoing generic penetration. However, the drug's established efficacy, the need for preservative-free formulations, and its role in critical care settings will ensure continued, albeit reduced, revenue generation. The market for generic enoxaparin sodium (preservative-free) is expected to stabilize and potentially grow as more healthcare providers and payers adopt cost-effective generic alternatives.
• Market Size (Enoxaparin Sodium): The global enoxaparin sodium market was valued at approximately $3.4 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of around 3.0% to reach approximately $4.2 billion by 2030. This overall market growth includes both branded and generic enoxaparin, with generics driving volume increases [1]. The preservative-free segment is a significant contributor to this market.

What are the Key Clinical and Regulatory Considerations for LOVENOX (Preservative-Free)?

The clinical utility and regulatory pathway for LOVENOX (preservative-free) are critical to its market performance and competitive positioning.

• Indications: LOVENOX is approved for:
  • Prevention of DVT and PE in patients undergoing abdominal surgery, hip replacement surgery, or knee replacement surgery.
  • Prevention of DVT and PE in medical patients who are at risk due to severely restricted mobility during acute illness.
  • Treatment of DVT and PE.
  • Reduction in the frequency of heart attack and stroke in patients with unstable angina or who have had a myocardial infarction not experiencing ST-segment elevation.
  • Prevention of ischemic complications in patients undergoing coronary artery bypass surgery.
• Preservative-Free Necessity: The preservative-free formulation is essential for neonates, pediatric patients, and patients with known hypersensitivity to preservatives or components of the drug product. It is also preferred in situations where preservatives might interfere with diagnostic tests or treatment protocols.
• Regulatory Pathway for Generics: Generic enoxaparin sodium products must demonstrate bioequivalence to the reference listed drug (LOVENOX). For LMWHs, bioequivalence is a complex assessment that considers not only plasma concentration-time profiles but also characteristics of the heparin molecule itself, such as molecular weight distribution, anti-Xa and anti-IIa activity, and other pharmacodynamic parameters [2]. Regulatory agencies, like the U.S. Food and Drug Administration (FDA), have specific guidance for the approval of generic enoxaparin.
• Manufacturing Complexity: The manufacturing of enoxaparin involves the controlled depolymerization of unfractionated heparin. Achieving a consistent molecular weight profile and impurity profile is crucial for safety and efficacy. This complexity has historically been a barrier to generic entry and a focus of patent protection.
• Post-Marketing Surveillance: Like all pharmaceuticals, LOVENOX and its generic equivalents are subject to post-marketing surveillance to monitor for adverse events and ensure continued safety and efficacy.
• Biosimilarity vs. Generics: It is important to note that enoxaparin sodium is a chemical entity, not a biologic. Therefore, the regulatory pathway is for generic drugs, not biosimilars. This distinction impacts the interchangeability and approval process.

Key Takeaways

• LOVENOX (preservative-free) has transitioned from a high-revenue blockbuster to a mature product facing significant market share erosion due to generic competition.
• The preservative-free formulation remains critical for specific patient populations and clinical scenarios, ensuring continued demand and market presence.
• While originator patents have expired, secondary patents and ongoing litigation have influenced the timeline and complexity of generic entry.
• The financial trajectory shows a sharp decline in branded LOVENOX sales, offset by a growing market for generic enoxaparin sodium, including preservative-free versions.
• Direct oral anticoagulants (DOACs) represent a broader competitive threat to the LMWH class, though enoxaparin retains its role in acute and high-risk settings where preservative-free is paramount.

Frequently Asked Questions

1. What is the primary indication where the preservative-free formulation of LOVENOX is critical? The preservative-free formulation is critical for neonates, pediatric patients, and individuals with known hypersensitivity to preservatives, ensuring safety and efficacy in these vulnerable populations and specific clinical contexts.

2. How does the manufacturing of enoxaparin sodium differ from standard heparin, and why is this relevant to patent and generic competition? Enoxaparin sodium is a low molecular weight heparin (LMWH) produced through controlled chemical or enzymatic depolymerization of unfractionated heparin. This process results in a specific molecular weight distribution, anti-Xa/anti-IIa activity ratio, and impurity profile that is proprietary and complex, forming the basis for many formulation and process patents, and posing challenges for generic manufacturers to replicate consistently.

3. What is the regulatory requirement for generic enoxaparin sodium to be considered bioequivalent to LOVENOX? Generic enoxaparin sodium must demonstrate bioequivalence not only through plasma concentration-time profiles but also by exhibiting comparable pharmacodynamic effects (anti-Xa and anti-IIa activity) and demonstrating a similar molecular weight distribution and impurity profile, as outlined by regulatory agencies like the FDA.

4. Beyond LOVENOX and its generics, what other drug classes compete for the anticoagulant market, and where do LMWHs still hold an advantage? Direct Oral Anticoagulants (DOACs) like rivaroxaban and apixaban compete broadly. LMWHs, including preservative-free enoxaparin, retain advantages in acute settings such as unstable angina or myocardial infarction, in patients with significant renal impairment where DOACs may be contraindicated or require dose adjustments, and during specific surgical interventions where predictable pharmacokinetics are essential.

5. What is the expected long-term market outlook for branded LOVENOX (preservative-free) in light of ongoing generic penetration? The long-term outlook for branded LOVENOX (preservative-free) is a continued decline in sales revenue as generic enoxaparin sodium captures a larger market share. However, its established clinical utility and the specific need for a preservative-free formulation will ensure a sustained, albeit smaller, revenue stream and market presence.

Citations

[1] Grand View Research. (2024). Enoxaparin Sodium Market Size, Share & Trends Analysis Report By Application, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/enoxaparin-sodium-market

[2] U.S. Food & Drug Administration. (2023). Guidance for Industry: ANDAs for Certain Molecular Entities and Products. Retrieved from https://www.fda.gov/media/70757/download